- Home
- Individualising Antithrombotic Strategies for Established Coronary Artery Disease
Individualising Antithrombotic Strategies for Established Coronary Artery Disease
- Intervention
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
Radcliffe Medical Education bring together an expert panel to address the importance of providing individualised antithrombotic treatment in Acute Coronary Syndrome (ACS) and Chronic Coronary Syndrome (CCS).
Chaired by Prof Marco Valgimigli (Instituto Cardiocentro Ticino, Lugano, CH), the panel review the two patient cases presented in phase one of this programme, present impactful new trial data and discuss practical solutions to common challenges experienced in real-world practice.
Further, the faculty review and summarise the new recommendations for antithrombotic treatment strategies in ACS and CCS patients with established coronary artery disease (CAD) made in the 2022 joint clinical consensus statement of the European Association of Percutaneous Coronary Intervention (EAPCI), Association for Acute Cardiovascular Care (ACVC) and European Association of Preventive Cardiology (EAPC).
Support Statement
This programme is supported by an unrestricted educational grant from AstraZeneca.
Disclosure
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘Individualising Antithrombotic Strategies for Established Coronary Artery Disease’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionalsand the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 90 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
- General Cardiologists
- Interventional Cardiologists
- Nurses
- HCPs
Learning Objectives
Upon completion of this activity, participants will be able to:
- Summarise current guidance for choosing antithrombotic therapy in established CAD
- Describe current gaps in clinical evidence and what is missing from current guidance
- Adopt an evidence-based approach for managing patients with ACS and CCS
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Presentation & Discussion | Patient Cases Revisited | 18 mins | Eliano Navarese (Toruń, PL) Pascal Vranckx (Hasselt, BE) |
| Presentation | Development of a Consensus for Antithrombotic Therapy in CAD | 15 mins | Marco Valgimigli (Lugano, CH) |
| Presentation | Antithrombotic Treatment Strategies in Patients With Established CAD: Results of Two Network Meta-Analyses | 15 mins | Eliano Navarese (Toruń, PL) |
| Presentation | Clinical Consensus Statements on Patients With ACS | 15 mins | Vijay Kunadian (Newcastle, UK) |
| Presentation | Clinical Consensus Statements on Patients With CCS | 10 mins | Pascal Vranckx (Hasselt, BE) |
| Discussion | Panel Discussion and Q&A | 15 mins | Marco Valgimigli (Lugano, CH) Vijay Kunadian (Newcastle, UK) Eliano Navarese (Toruń, PL) Pascal Vranckx (Hasselt, BE) |
Patient Cases Revisited
Duration: 18 mins
Speakers: Eliano Navarese (Toruń, PL) Pascal Vranckx (Hasselt, BE)
Development of a Consensus for Antithrombotic Therapy in CAD
Duration: 15 mins
Speakers: Marco Valgimigli (Lugano, CH)
Antithrombotic Treatment Strategies in Patients With Established CAD: Results of Two Network Meta-Analyses
Duration: 15 mins
Speakers: Eliano Navarese (Toruń, PL)
Clinical Consensus Statements on Patients With ACS
Duration: 15 mins
Speakers: Vijay Kunadian (Newcastle, UK)
Clinical Consensus Statements on Patients With CCS
Duration: 10 mins
Speakers: Pascal Vranckx (Hasselt, BE)
Panel Discussion and Q&A
Duration: 15 mins
Speakers: Marco Valgimigli (Lugano, CH) Vijay Kunadian (Newcastle, UK) Eliano Navarese (Toruń, PL) Pascal Vranckx (Hasselt, BE)
Related Courses
- 1.00
Published:
Learning objectives
- Recall current and predicted trends in TAVI with respect to preserving coronary access
- Consider determining factors for choosing valves in low risk populations
- Discuss solutions for maximising valve durability and haemodynamics and for treating degenerated TAVI
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI